Copper peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
== Interactions == Elagolix has a number of potential drug interactions with other medications. Elagolix is a substrate of the cytochrome P450 (CYP450) enzyme CYP3A, and inhibitors and inducers of CYP3A4 may alter the metabolism of elagolix and increase or decrease its circulating levels. The strong CYP3A4 inhibitor ketoconazole has been found to increase peak levels of and total exposure to a single 150 mg dose of elagolix by about 2-fold. Paradoxically, rifampin, a strong inducer of CYP3A4 and other CYP450 enzymes, increased peak levels of and total exposure to a single 150 mg dose of elagolix as well. A single dose of rifampin increased peak levels of elagolix by 4.4-fold and total exposure by 5.6-fold, whereas continuous rifampin therapy increased peak levels of elagolix by 2-fold and total exposure by 1.7-fold. The use of elagolix at 200 mg twice per day concomitantly with rifampin is not recommended, whereas the concomitant use of elagolix at 150 mg once per day with rifampin should be limited to 6 months. No significant changes in exposure to elagolix were observed with concomitant administration of rosuvastatin (a substrate of OATP1B1, OATP1B3, and BCRP), sertraline (a moderate inhibitor of CYP2D6 and CYP2B6), or fluconazole (a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4). Elagolix is a substrate of the hepatic OATP1B1 transporter. Levels of elagolix have been found to be increased by 78% in people with a genotype characterized by reduced OATP1B1 transporter function.
== Research == Alström Syndrome was first discovered by Swedish psychiatrist, Carl-Henry Alström and his three associates, B. Hallgren, I. B. Nilsson and H. Asander, in 1946. Alström and his colleagues published their first manuscript in 1959, which contained a very thorough investigation of three patients with a recessive combination of retinal degeneration, obesity, sensorineural hearing loss, and diabetes, which are all extremely common symptoms in AS. The syndrome was first known as Alström-Hallgren Syndrome, but has since been more widely known as just Alström Syndrome. In 2001 Jackson Laboratory in Bar Harbor, Maine, USA with the University of Southampton, UK isolated the single gene (ALMS1) responsible for Alström syndrome. The Jackson Laboratory created the very first mouse model for AS, Alms1-/-, or more colloquially known as "Carl Henry Mouse" in 2004. These mice continue to be used in research studies to simulate the symptoms of an individual with AS.
Exclusion of other conditions that have overlapping symptoms Magnetic resonance imaging (MRI) is a medical imaging technique used in radiology to visualize internal structures of the body in detail. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body. This method is reliable because MRIs assess changes in proton density. "Spots" can occur as a result of changes in brain water content. Nerve Conduction Studies utilize electrical stimulation of nerves to study sensory and motor nerve conduction. Evoked potential is an electrical potential recorded from the nervous system following the presentation of a stimulus as detected by electroencephalography (EEG), electromyography (EMG), or other electrophysiological recording method. Cerebrospinal fluid analysis (CSF) can be extremely beneficial in the diagnosis of central nervous system infections. A CSF culture examination may yield the microorganism that caused the infection. Quantitative proton magnetic resonance spectroscopy (MRS) is a noninvasive analytical technique that has been used to study metabolic changes in brain tumors, strokes, seizure disorders, Alzheimer's disease, depression, and other diseases affecting the brain. It has also been used to study the metabolism of other organs such as muscles. Diagnostic criteria refers to a specific combination of signs, symptoms, and test results that the clinician uses in an attempt to determine the correct diagnosis.
17 July – Members of Unison at 14 Scottish council areas, including Glasgow, Perth and Kinross and Dumfries and Galloway, vote to take industrial action after describing a pay offer from COSLA as "inadequate". 19 July – Unison rejects the latest offer from Cosla aimed at preventing strikes by refuse collectors, which was worth 3.2%. 21 July – Data from Public Health Scotland for the week ending 14 July indicates there were 1,130 cases of COVID-19 in Scotland, but the health body believes cases may have peaked. 22 July – Following the death of 17-year-old Jonathan Beadle at Polmont Young Offenders Institution on Saturday 13 July, the Scottish Government announces that nobody under the age of 18 will be kept in prison in Scotland from the week beginning 2 September. Unite and the GMB follow Unison in rejecting the latest pay offer for refuse workers from Cosla. 23 July – The family of Allan Marshall, who died after being restrained by 17 prison officers at HMP Edinburgh in 2015, are to sue the Scottish Government under human rights legislation in what is believed to be the first case of its kind. 24 July – Researchers from the Scottish Association for Marine Science report evidence of dark oxygen being produced from manganese nodules on the seafloor. It was previously assumed that almost all the free oxygen (O2) on Earth was created through photosynthesis, which requires sunlight. The research has since come under criticism for methodological and ethical issues.
A bursa is a small fluid-filled sac made of white fibrous tissue and lined with synovial membrane. Bursa may also be formed by a synovial membrane that extends outside of the joint capsule. It provides a cushion between bones and tendons or muscles around a joint; bursa are filled with synovial fluid and are found around almost every major joint of the body.
Sources: en.wikipedia.org
== Interpretation == In the United States and in most European countries creatinine is usually reported in mg/dL, whereas in Canada, Australia, and a few European countries, such as the UK, μmol/L is the usual unit. One mg/dL of creatinine equals 88.4 μmol/L. The typical human reference ranges for serum creatinine are 0.5 mg/dL to 1.0 mg/dL (about 45 μmol/L to 90 μmol/L) for women and 0.7 mg/dL to 1.2 mg/dL (60 μmol/L to 110 μmol/L) for men. The significance of a single creatinine value must be interpreted in light of the patient's muscle mass. Patients with greater muscle mass have higher creatinine concentrations.
==== 1916–17: Change in British Government ==== In terms of British politics, the declaration resulted from the coming into power of Lloyd George and his Cabinet, which had replaced the H. H. Asquith led-Cabinet in December 1916. Whilst both Prime Ministers were Liberals and both governments were wartime coalitions, Lloyd George and Balfour, appointed as his Foreign Secretary, favoured a post-war partition of the Ottoman Empire as a major British war aim, whereas Asquith and his Foreign Secretary, Sir Edward Grey, had favoured its reform. Two days after taking office, Lloyd George told General Robertson, the Chief of the Imperial General Staff, that he wanted a major victory, preferably the capture of Jerusalem, to impress British public opinion, and immediately consulted his War Cabinet about a "further campaign into Palestine when El Arish had been secured." Subsequent pressure from Lloyd George, over the reservations of Robertson, resulted in the recapture of the Sinai for British-controlled Egypt, and, with the capture of El Arish in December 1916 and Rafah in January 1917, the arrival of British forces at the southern borders of the Ottoman Empire. Following two unsuccessful attempts to capture Gaza between 26 March and 19 April, a six-month stalemate in Southern Palestine began; the Sinai and Palestine Campaign would not make any progress into Palestine until 31 October 1917.
==== Iron ==== Iron is stored as iron(III) in ferritin. The exact nature of the binding site has not yet been determined. The iron appears to be present as a hydrolysis product such as FeO(OH). Iron is transported by transferrin whose binding site consists of two tyrosines, one aspartic acid and one histidine. The human body has no controlled mechanism for excretion of iron. This can lead to iron overload problems in patients treated with blood transfusions, as, for instance, with β-thalassemia. Iron is actually excreted in urine and is also concentrated in bile which is excreted in feces.
Garden parsley is a bright green, biennial plant in temperate climates, or an annual herb in subtropical and tropical areas. Where it grows as a biennial, in the first year, it forms a rosette of tripinnate leaves 10–25 cm (3.9–9.8 in) long with numerous 1–3 cm leaflets, and a taproot used as a food store over the winter. In the second year, it grows a flowering stem to 75 cm (30 in) tall with sparser leaves and flat-topped 3–10 cm diameter umbels with numerous 2 mm diameter yellow to yellowish-green flowers. The seeds are ovoid, 2–3 mm long, with prominent style remnants at the apex. One of the compounds of the essential oil is apiole. The plant normally dies after seed maturation.
Butyrfentanyl or butyrylfentanyl is a potent short-acting synthetic opioid analgesic drug. It is an analog of fentanyl with around one quarter of its potency. One of the first mentions of this drug can be found in document written by The College on Problem of Drug Dependence, where it is mentioned as N-butyramide fentanyl analog. This document also states that the article describing its clinical effects (analgesic studies, μ-, δ-, κ-opioid receptor binding, and in vitro measures of drug efficacy, antinociceptive, and narcotic properties) was published in 1987. It is an agonist for the μ-opioid receptors. Butyrfentanyl has no current legitimate clinical applications; however, it is being sold as a designer drug. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea, and potentially serious respiratory depression which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.